Recurrent ocular toxoplasmosis in patients treated with systemic corticosteroids

Retina

Volumn 16, Issue 5, 1996, Pages 383-387

  Morhun, Patrick J ^a   Weisz, James M ^a   Elias, Samuel J ^a   Holland, Gary N ^a  

^a JULES STEIN EYE INSTITUTE   (United States)

Author keywords

corticosteroids; immunosuppression; ocular; reactivation; recurrence; toxoplasmosi s

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CLINDAMYCIN; CORTICOSTEROID; FOLINIC ACID; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE ACETATE; PREDNISONE; PYRIMETHAMINE; SULFADIAZINE; SULFAFURAZOLE; TRISULFAPYRIMIDINE;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CHILD; CHORIORETINITIS; CORTICOSTEROID THERAPY; EYE INFECTION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; ORAL DRUG ADMINISTRATION; RECURRENT INFECTION; RETROSPECTIVE STUDY; TOPICAL DRUG ADMINISTRATION; TOXOPLASMOSIS; TREATMENT OUTCOME; VISUAL ACUITY;

ADOLESCENT; ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, PROTOZOAN; ANTIDOTES; CHILD; CHORIORETINITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PREDNISOLONE; PYRIMETHAMINE; RECURRENCE; SULFADIAZINE; TOXOPLASMA; TOXOPLASMOSIS, OCULAR;

EID: 0029965584     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-199616050-00003     Document Type: Article

References (32)

1. O'Connor GR, Remington JS. Therapy of toxoplasmic retinochoroiditis. Arch Ophthalmol 1964;71:883-884.
2. O'Connor GR. Manifestations and management of ocular toxoplasmosis. Bull NY Acad Med 1974;50:192-210.
3. O'Connor GR, Frenkel JK. Dangers of steroid treatment in toxoplasmosis. Arch Ophthalmol 1976;94:213.
4. Perkins ES. Ocular toxoplasmosis. Br J Ophthalmol 1973; 57:1-17.
5. O'Connor GR. Factors related to the initiation and recurrence of uveitis: XL, Edward Jackson memorial lecture. Am J Ophthalmol 1983;96:577-599.
6. Wong SY, Israelski DM, Remington JS. AIDS-associated toxoplasmosis. In: Sande MA, Volberding PA, eds. The Medical Management of AIDS. 4th ed. Philadelphia, PA: WB Saunders Co; 1994:460-492.
7. Zangerle R, Allerberger F, Pohl P, et al. High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii. Med Microbiol Immunol (Berl) 1991;180:59-66.
8. Sabates R, Pruett RC, Brockhurst RJ. Fulminant ocular toxoplasmosis. Am J Ophthalmol 1981;92:497-503.
9. Cohen SN. Toxoplasmosis in patients receiving immunosuppressive therapy. JAMA 1970;211:657-670.
10. Cogan DG. Immunosuppression and eye disease. Am J Ophthalmol 1977;83:777-788.
11. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992;15:211-222.
12. Holland GN, Engstrom RE Jr, Glasgow BJ, et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1988;106:653-667.
13. Zimmerman LE. Ocular pathology of toxoplasmosis. Surv Ophthalmol 1961;6:832-838.
14. Nozik RA, O'Connor GR. Studies on experimental ocular toxoplasmosis in the rabbit: II, attempts to stimulate recurrences by local trauma, epinephrine, and corticosteroids. Arch Ophthalmol 1970;84:788-791.
15. Kaufman HE. The effect of corticosteroids on experimental ocular toxoplasmosis. Am J Ophthalmol 1960;50:919-926.
16. Frenkel JK. Effects of cortisone, total body irradiation and nitrogen mustard on chronic, latent toxoplasmosis. Am J Pathol 1957;33:618-619.
17. Goust JM, Stevenson H, Galbraith R, Virella G. Immunosuppression and immunomodulation. Immunol Ser 1993;58: 465-480.
18. Holland GN, O'Connor GR, Diaz RF, et al. Ocular toxoplasmosis in immunosuppressed nonhuman primates. Invest Ophthalmol Vis Sci 1988;29:835-842.
19. Parillo JE, Fauci AS. Mechanisms of glucocorticoid action on immune processes. Ann Rev Pharmacol Toxicol 1979; 19:179-201.
20. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 1989;11:954-963.
21. Claman HN. Glucocorticoids II the clinical responses. Hosp Pract 1983;18:143-151.
22. Chamberlin P, Meyer WJ III. Management of pituitary-adrenal suppression secondary to corticosteroid therapy. Pediatrics 1981;67:245-251.
23. McEvoy GK, Litvak K, Welsh OH Jr, et al, eds. American Hospital Formulary Service Drug Information. Bethesda, MD: American Society of Hospital Pharmacists Inc; 1993:1888.
24. Smith RE, Ganley JP. Ophthalmic survey of a community: I, abnormalities of the ocular fundus. Am J Ophthalmol 1972;74:1126-1130.
25. Engstrom RE Jr, Holland GN, Nussenblatt RB, Jabs DA. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol 1991;111:601-610.
26. Nicholson DH, Wolchok EB. Ocular toxoplasmosis in an adult receiving long-term corticosteroid therapy. Arch Ophthalmol 1976;94:248-254.
27. Tabbara KF. Toxoplasmosis. In: Tasman W, Jaeger EA, eds. Clinical Ophthalmology. Vol 4. Philadelphia, PA: JB Lippincott Co; 1991:46:1-23.
28. Peacock JE Jr, Greven CM, Cruz JM, Hurd DD. Reactivation toxoplasmic retinochoroiditis in patients undergoing bone marrow transplantation: is there a role for chemoprophylaxis? Bone Marrow Transplant 1995;15:983-987.
29. Mantegazza R, Antozzi C, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988;235:449-453.
30. Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Ann Int Med 1975;83: 597-605.
31. Sztejnbok M, Stewart A, Diamond H, Kaplan D. Azathioprine in the treatment of systemic lupus erythematosus: a controlled study. Arthritis Rheum 1971;14:639-645.
32. Frenkel JK. Pathogenesis of toxoplasmosis with a consideration of cyst rupture in Besnoitia infection. Surv Ophthalmol 1961;6:799-825.